FDA updates GMPs
This article was originally published in The Tan Sheet
FDA revises its good manufacturing practice regulations for finished pharmaceuticals to clarify some of the requirements and harmonize them with other FDA standards and international GMPs as part of its first phase of its incremental approach to modifying the GMPs for finished drugs, according to a final rule published in the Sept. 8 Federal Register. Specifically, the rule revises requirements related to aseptic processing, verification of performance of operations by a second individual and use of asbestos filters. The rule applies to all finished pharmaceuticals, both under new drug applications and OTC monographs. "We are pleased to see the agency updating GMPs and feel it is important they continue to do so," commented Elizabeth Funderburk, Consumer Products Healthcare Association director of communications
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.